Get access

Another complication of natalizumab treatment? Taking the challenge


  • Potential conflict: N.G. has received honoraria for lectures from, served as principal investigator, member of steering committees, or member of advisory boards in clinical trials sponsored by, or has had consulting agreements over the past 5 years with Bayer-Schering, Biogen-Idec, Merck-Serono, Novartis, Sanofi-Aventis, and other companies involved in the development of MS therapeutics. N.G. has received research support by the Swiss National Research Foundation, the National Center for Competence in Research Neural Plasticity and Repair, Biogen-Idec, Merck-Serono SA Geneva, the Swiss Multiple Sclerosis Society, the 3R Research Foundation Switzerland, and the Koetser Foundation for Brain Research.

No abstract is available for this article.